Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series
Tomaso Beringheli, Clément Javaux, Sandrine Roux, Evelyne Braun, Pierre Chauvelot, Sylvain Goutelle, Thomas Briot, Judith Cottin, Céline Dupieux, Johanna Boulant, Anne Conrad, Florence Ader, Tristan Ferry, Florent Valour; Lyon BJI study group
Due to its potentially better long-term haematologic tolerance compared to linezolid, tedizolid represents an attractive option for prolonged antibiotic therapy in complicated/chronic Gram-positive infections. However, there is little information regarding the risk of peripheral neurological toxicity, representing another obstacle to the extended use of oxazolidinones. Reporting neurologic adverse events occurring during tedizolid therapy for chronic implant-associated infections.
